Dr Reddy's Labs

{
  "main_header": {
    "sid": 734514,
    "name": "Dr Reddy's Labs",
    "stock_name": "Dr Reddy's Labs",
    "full_name": "Dr Reddys Laboratories Ltd",
    "name_url": "stocks-analysis/dr-reddy-s-labs",
    "exchange": 1,
    "exchangecode": "",
    "primexch": 1,
    "country_id": 34,
    "currency": "INR",
    "cmp": "1,322.90",
    "chg": -6.9,
    "chgp": "-0.52%",
    "dir": -1,
    "prev_price": "1,329.80",
    "mcapval": "111,260.00 Cr",
    "mcap": "Large Cap",
    "scripcode": "500124",
    "symbol": "DRREDDY",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "India SENSEX",
    "isin": "INE089A01031",
    "curr_date": "Apr 30",
    "curr_time": "",
    "bse_nse_vol": "12.89 lacs",
    "exc_status": "Active",
    "traded_date": "Apr 30, 2026",
    "traded_date_str": "2026 04 30",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/dr-reddy-s-labs-734514-1&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0,
      "all_data": []
    }
  },
  "news": {
    "results": [
      {
        "title": "P/E at 19.96 vs Industry's 33.42: What the Data Shows for Dr Reddys Laboratories Ltd",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/dr-reddys-laboratories-ltd-navigating-nifty-50-membership-and-institutional-dynamics-3969660",
        "imagepath": "",
        "date": "2026-04-30 09:20:50",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <p><strong>Significance of Nifty 50 Membership</strong></p>\n                <p>As a constituent of the Nifty 50, Dr Reddys Laboratories Ltd holds a pivotal role in representing the Pharmaceuticals & Biotechnology sector within India’s premier equity benchmark. This membership not only enhances the stock’s visibility among domestic and international investors but also ensures inclusion in numerous index-tracking funds and exchange-traded funds (ETFs). The company’s market capitalisation of ₹1,11,063.63 crores firmly places it in the large-cap category, reinforcing its weight within the index and its influence on overall market movements.</p>\n                <p>Being part of the Nifty 50 also subjects Dr Reddys Laboratories to heightened scrutiny and performance expectations. The index’s c..."
      },
      {
        "title": "P/E at 20.31 vs Industry's 33.32: What the Data Shows for Dr Reddys Laboratories Ltd",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/dr-reddys-laboratories-ltd-strengthens-position-as-key-nifty-50-constituent-amid-institutional-interest-3967724",
        "imagepath": "",
        "date": "2026-04-29 09:20:49",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <p><strong>Significance of Nifty 50 Membership</strong></p>\n                <p>Being a constituent of the Nifty 50 index confers considerable advantages on Dr Reddys Laboratories Ltd, not least in terms of enhanced visibility and liquidity. The index, widely regarded as the benchmark for Indian equity markets, attracts significant passive investment flows from index funds and exchange-traded funds (ETFs). Consequently, inclusion ensures a steady demand for the stock, which can help stabilise price movements and reduce volatility.</p>\n                <p>Dr Reddys Laboratories, with a market capitalisation of approximately ₹1,12,353.17 crores, is classified as a large-cap stock, making it a cornerstone holding for many institutional portfolios. Its presence in the Nifty 50 also signals a l..."
      },
      {
        "title": "P/E at 20.00 vs Industry's 33.33: What the Data Shows for Dr Reddys Laboratories Ltd",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/dr-reddys-laboratories-ltd-strengthens-position-amid-nifty-50-membership-and-institutional-interest-3966031",
        "imagepath": "",
        "date": "2026-04-28 09:20:49",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <p><strong>Valuation Picture: Discount Amidst Sector Premiums</strong></p>\n                <p><a href=\"https://www.marketsmojo.com/stocks-analysis/dr-reddy's-labs-734514-0\" class=\"stk\">Dr Reddys Laboratories Ltd</a> trades at a P/E of 20.00, markedly below the Pharmaceuticals & Biotechnology industry average of 33.33. This 40% discount suggests the market is pricing in either a more conservative growth outlook or risk factors not fully reflected in sector valuations. The sizeable premium commanded by peers in the industry contrasts with <a href=\"https://www.marketsmojo.com/stocks-analysis/dr-reddy's-labs-734514-0\" class=\"stk\">Dr Reddys Laboratories Ltd</a>’s more modest multiple, raising questions about the sustainability of this valuation gap — <a href=\"https://www.marketsmojo.com/stock..."
      },
      {
        "title": "P/E at 19.67 vs Industry's 32.51: What the Data Shows for Dr Reddys Laboratories Ltd",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/dr-reddys-laboratories-ltd-strengthens-position-as-key-nifty-50-constituent-amid-robust-institutional-interest-3963830",
        "imagepath": "",
        "date": "2026-04-27 09:20:48",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <p><strong>Valuation Picture: Discount Amidst Sector Premiums</strong></p>\n                <p>The current P/E of 19.67 for <a href=\"https://www.marketsmojo.com/stocks-analysis/dr-reddy's-labs-734514-0\" class=\"stk\">Dr Reddys Laboratories Ltd</a> stands in stark contrast to the industry average of 32.51, signalling a valuation discount of nearly 40%. This divergence suggests the market is pricing in either a more conservative growth outlook or perceived risks relative to its pharmaceutical peers. The sector’s elevated P/E typically reflects expectations of robust earnings growth and innovation, yet <a href=\"https://www.marketsmojo.com/stocks-analysis/dr-reddy's-labs-734514-0\" class=\"stk\">Dr Reddys Laboratories Ltd</a> appears to be trading on more subdued multiples. This valuation gap invi..."
      },
      {
        "title": "Dr Reddys Laboratories Gains 6.51%: 3 Key Factors Driving the Week’s Rally",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/dr-reddys-laboratories-gains-651-3-key-factors-driving-the-weeks-rally-3962622",
        "imagepath": "",
        "date": "2026-04-25 16:00:04",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <div class=\"highlight-box\">\n                    <h3>Key Events This Week</h3>\n                    <p><strong>Apr 20:</strong> Stock opens week at Rs.1,232.25, down 0.25% amid flat Sensex</p>\n                    <p><strong>Apr 21:</strong> Continued decline to Rs.1,220.75 despite Sensex rallying 0.77%</p>\n                    <p><strong>Apr 22:</strong> Stock dips further to Rs.1,217.00 as Sensex slips 0.23%</p>\n                    <p><strong>Apr 23:</strong> Sharp rebound with 9.54% surge to Rs.1,333.05 on technical upgrade</p>\n                    <p><strong>Apr 24:</strong> Slight pullback to Rs.1,315.85 as MarketsMOJO upgrades rating to Buy</p>\n                </div>\n\n                <div class=\"stats-row\">\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Open</di..."
      },
      {
        "title": "Dr Reddys Laboratories Upgraded to Buy on Strong Technical and Fundamental Signals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/dr-reddys-laboratories-upgraded-to-buy-on-strong-technical-and-fundamental-signals-3960231",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/DrReddysLaborat_mojoScore_3960231.png",
        "date": "2026-04-24 08:10:48",
        "description": "Dr Reddys Laboratories Ltd has seen its investment rating upgraded from Hold to Buy, driven primarily by a marked improvement in technical indicators alongside solid long-term fundamentals. Despite recent quarterly financial setbacks, the company’s robust valuation metrics, quality scores, and positive technical trends have convinced analysts to revise their outlook favourably."
      },
      {
        "title": "Dr Reddys Laboratories Ltd Sees Strong Technical Momentum Shift Amid Market Rally",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/dr-reddys-laboratories-ltd-sees-strong-technical-momentum-shift-amid-market-rally-3960105",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/DrReddysLaborat_technicaldot_3960105.png",
        "date": "2026-04-24 08:02:18",
        "description": "Dr Reddys Laboratories Ltd has witnessed a significant shift in its technical momentum, with key indicators signalling a transition from a mildly bullish to a bullish trend. The stock surged 9.54% on 24 Apr 2026, closing at ₹1,333.05, reflecting renewed investor confidence amid positive technical signals and a recent upgrade in its Mojo Grade from Hold to Buy."
      },
      {
        "title": "Dr Reddys Laboratories Ltd Surges 3.57% to Day's High of Rs 1259 — Outperforms Sector by 2.65 Percentage Points",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/dr-reddys-laboratories-ltd-hits-intraday-high-with-357-surge-on-23-apr-2026-3958659",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/DrReddysLaborat_priceRelatedfactors_3958659.png",
        "date": "2026-04-23 09:30:56",
        "description": "The Sensex declined 0.75% on 23 Apr 2026 while Dr Reddys Laboratories Ltd advanced 3.57%, outperforming its Pharmaceuticals &amp; Biotechnology sector by 2.65 percentage points. This strong single-session gain stands out as a stock-specific event amid a broadly weak market backdrop."
      },
      {
        "title": "P/E at 18.24 vs Industry's 32.49: What the Data Shows for Dr Reddys Laboratories Ltd",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/dr-reddys-laboratories-ltd-navigating-nifty-50-membership-and-institutional-shifts-3958641",
        "imagepath": "",
        "date": "2026-04-23 09:20:43",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <p><strong>Significance of Nifty 50 Membership</strong></p>\n                <p>Being part of the Nifty 50 index places Dr Reddys Laboratories Ltd at the forefront of India’s equity markets. This membership not only reflects the company’s robust market capitalisation—currently standing at ₹1,04,749.45 crores—but also ensures heightened visibility among institutional investors and index funds. The inclusion in this benchmark index often leads to increased liquidity and trading volumes, as passive funds tracking the Nifty 50 adjust their portfolios accordingly.</p>\n                <p>Moreover, the company’s large-cap status within the Pharmaceuticals & Biotechnology sector positions it as a bellwether for industry trends. Its performance is closely monitored by market participants as an ind..."
      }
    ],
    "total": 540,
    "sid": "734514",
    "stock_news_url": "https://www.marketsmojo.com/news/dr-reddys-laboratories-734514"
  },
  "announcements": [
    {
      "details": "Dr. Reddy's Laboratories Limited has submitted to the Exchange a copy of Disclosure of Related Party Transactions for the period ended September 30, 2019.",
      "source": "NSE",
      "caption": "Dr. Reddy's Laboratories Limited - Other General Purpose",
      "datetime": "28-Nov-2019"
    },
    {
      "details": "Dr. Reddy's Laboratories Limited has informed the Exchange regarding a press release dated November 22, 2019, titled \"Dr. Reddy's Laboratories announces launch of",
      "source": "NSE",
      "caption": "Dr. Reddy's Laboratories Limited - Press Release",
      "datetime": "22-Nov-2019"
    },
    {
      "details": "Dr. Reddy's Laboratories Limited has informed the Exchange regarding a press release dated November 14, 2019, titled \"Dr. Reddy s Laboratories enters Nutrition Segment with Celevida in India.\".",
      "source": "NSE",
      "caption": "Dr. Reddy's Laboratories Limited - Press Release",
      "datetime": "14-Nov-2019"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "",
      "data": [
        {
          "title": "BOARD MEETING",
          "txt": "12 May 2026"
        }
      ]
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Dr Reddys Laboratories Ltd has declared <strong>800%</strong> dividend, ex-date: 10 Jul 25",
          "dt": "2025-07-10",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "",
      "data": [
        {
          "txt": "Dr Reddys Laboratories Ltd has announced <strong>1:5</strong> stock split, ex-date: 28 Oct 24",
          "dt": "2024-10-28",
          "middle_text": "Split"
        }
      ]
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "",
      "data": [
        {
          "txt": "Dr Reddys Laboratories Ltd has announced <strong>1:1</strong> bonus issue, ex-date: 28 Aug 06",
          "dt": "2006-08-28",
          "middle_text": "Bonus Alert"
        }
      ]
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

P/E at 19.96 vs Industry's 33.42: What the Data Shows for Dr Reddys Laboratories Ltd

2026-04-30 09:20:50

Significance of Nifty 50 Membership

As a constituent of the Nifty 50, Dr Reddys Laboratories Ltd holds a pivotal role in representing the Pharmaceuticals & Biotechnology sector within India’s premier equity benchmark. This membership not only enhances the stock’s visibility among domestic and international investors but also ensures inclusion in numerous index-tracking funds and exchange-traded funds (ETFs). The company’s market capitalisation of ₹1,11,063.63 crores firmly places it in the large-cap category, reinforcing its weight within the index and its influence on overall market movements.

Being part of the Nifty 50 also subjects Dr Reddys Laboratories to heightened scrutiny and performance expectations. The index’s c...

Read full news article

P/E at 20.31 vs Industry's 33.32: What the Data Shows for Dr Reddys Laboratories Ltd

2026-04-29 09:20:49

Significance of Nifty 50 Membership

Being a constituent of the Nifty 50 index confers considerable advantages on Dr Reddys Laboratories Ltd, not least in terms of enhanced visibility and liquidity. The index, widely regarded as the benchmark for Indian equity markets, attracts significant passive investment flows from index funds and exchange-traded funds (ETFs). Consequently, inclusion ensures a steady demand for the stock, which can help stabilise price movements and reduce volatility.

Dr Reddys Laboratories, with a market capitalisation of approximately ₹1,12,353.17 crores, is classified as a large-cap stock, making it a cornerstone holding for many institutional portfolios. Its presence in the Nifty 50 also signals a l...

Read full news article

P/E at 20.00 vs Industry's 33.33: What the Data Shows for Dr Reddys Laboratories Ltd

2026-04-28 09:20:49

Valuation Picture: Discount Amidst Sector Premiums

Dr Reddys Laboratories Ltd trades at a P/E of 20.00, markedly below the Pharmaceuticals & Biotechnology industry average of 33.33. This 40% discount suggests the market is pricing in either a more conservative growth outlook or risk factors not fully reflected in sector valuations. The sizeable premium commanded by peers in the industry contrasts with Dr Reddys Laboratories Ltd’s more modest multiple, raising questions about the sustainability of this valuation gap — Read full news article

P/E at 19.67 vs Industry's 32.51: What the Data Shows for Dr Reddys Laboratories Ltd

2026-04-27 09:20:48

Valuation Picture: Discount Amidst Sector Premiums

The current P/E of 19.67 for Dr Reddys Laboratories Ltd stands in stark contrast to the industry average of 32.51, signalling a valuation discount of nearly 40%. This divergence suggests the market is pricing in either a more conservative growth outlook or perceived risks relative to its pharmaceutical peers. The sector’s elevated P/E typically reflects expectations of robust earnings growth and innovation, yet Dr Reddys Laboratories Ltd appears to be trading on more subdued multiples. This valuation gap invi...

Read full news article

Dr Reddys Laboratories Gains 6.51%: 3 Key Factors Driving the Week’s Rally

2026-04-25 16:00:04

Key Events This Week

Apr 20: Stock opens week at Rs.1,232.25, down 0.25% amid flat Sensex

Apr 21: Continued decline to Rs.1,220.75 despite Sensex rallying 0.77%

Apr 22: Stock dips further to Rs.1,217.00 as Sensex slips 0.23%

Apr 23: Sharp rebound with 9.54% surge to Rs.1,333.05 on technical upgrade

Apr 24: Slight pullback to Rs.1,315.85 as MarketsMOJO upgrades rating to Buy

Week OpenRead full news article

Dr Reddys Laboratories Upgraded to Buy on Strong Technical and Fundamental Signals

2026-04-24 08:10:48

Dr Reddys Laboratories Ltd has seen its investment rating upgraded from Hold to Buy, driven primarily by a marked improvement in technical indicators alongside solid long-term fundamentals. Despite recent quarterly financial setbacks, the company’s robust valuation metrics, quality scores, and positive technical trends have convinced analysts to revise their outlook favourably.

Read full news article

Dr Reddys Laboratories Ltd Sees Strong Technical Momentum Shift Amid Market Rally

2026-04-24 08:02:18

Dr Reddys Laboratories Ltd has witnessed a significant shift in its technical momentum, with key indicators signalling a transition from a mildly bullish to a bullish trend. The stock surged 9.54% on 24 Apr 2026, closing at ₹1,333.05, reflecting renewed investor confidence amid positive technical signals and a recent upgrade in its Mojo Grade from Hold to Buy.

Read full news article

Dr Reddys Laboratories Ltd Surges 3.57% to Day's High of Rs 1259 — Outperforms Sector by 2.65 Percentage Points

2026-04-23 09:30:56

The Sensex declined 0.75% on 23 Apr 2026 while Dr Reddys Laboratories Ltd advanced 3.57%, outperforming its Pharmaceuticals & Biotechnology sector by 2.65 percentage points. This strong single-session gain stands out as a stock-specific event amid a broadly weak market backdrop.

Read full news article

P/E at 18.24 vs Industry's 32.49: What the Data Shows for Dr Reddys Laboratories Ltd

2026-04-23 09:20:43

Significance of Nifty 50 Membership

Being part of the Nifty 50 index places Dr Reddys Laboratories Ltd at the forefront of India’s equity markets. This membership not only reflects the company’s robust market capitalisation—currently standing at ₹1,04,749.45 crores—but also ensures heightened visibility among institutional investors and index funds. The inclusion in this benchmark index often leads to increased liquidity and trading volumes, as passive funds tracking the Nifty 50 adjust their portfolios accordingly.

Moreover, the company’s large-cap status within the Pharmaceuticals & Biotechnology sector positions it as a bellwether for industry trends. Its performance is closely monitored by market participants as an ind...

Read full news article

View All News